DelveInsight’s, “Advanced Hepatocellular Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape. It covers the Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report

• DelveInsight’s Advanced Hepatocellular Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Hepatocellular Carcinoma treatment.
• The leading companies working in the Advanced Hepatocellular Carcinoma market include CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
• Promising Advanced Hepatocellular Carcinoma Pipeline Therapies in the various stages of development include Enzalutamide, ABT-869, Durvalumab, Tremelimumab, Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules, Donafenib Tosilate Tablets, Toripalimab Injection, IBI308 200mg, Lenvatinib, Pembrolizumab, Cabozantinib, AEG35156 antisense IV infusion, Sorafenib, Z-208, Octreotide, and others.
• December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab and Sorafenib. The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
• December 2023: TaiRx Inc. announced a study of Phase 2 clinical trials for Nivolumab Injection [Opdivo] and CVM-1118. CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.
• On April 2023, Astellas Pharma Inc. announced a study of Phase 2 clinical trials for Enzalutamide. The purpose of the study was to evaluate the efficacy of enzalutamide in participants with advanced hepatocellular carcinoma (HCC) as measured by overall survival (OS).
• On August 2023, AstraZeneca announced a study of Phase 3 clinical trials for Durvalumab and Tremelimumab. This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
• On August 2023, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. announced a study of Phase 1 Clinical Trials for Penpulimab injection, TQB2618 injection and Anlotinib Hydrochloride Capsules. This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQB2618 injection combined with penpulimab injection and Anlotinib Hydrochloride Capsules in patients with advanced HCC.

 

Request a sample and discover the recent advances in Advanced Hepatocellular Carcinoma Treatment Drugs @ Advanced Hepatocellular Carcinoma Infection Pipeline Report

 

The Advanced Hepatocellular Carcinoma  pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Hepatocellular Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Hepatocellular Carcinoma clinical trial landscape.

 

Advanced Hepatocellular Carcinoma Overview

Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause of death by cancer each year. Unfortunately, considerable number of patients are diagnosed at advanced stage unsuitable for surgery or local treatment with poor prognosis and a median overall survival (OS) of about 6 months.

 

Find out more about Advanced Hepatocellular Carcinoma Treatment Landscape @ Drugs for Advanced Hepatocellular Carcinoma Treatment

 

Advanced Hepatocellular Carcinoma Emerging Drugs Profile

• Tivozanib : AVEO Oncology
• Nofazinlimab: CStone Pharmaceuticals
• ECT 204: Eureka Therapeutics
• Sintilimab: Eli Lilly and Company/Innovent

 

Advanced Hepatocellular Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Advanced Hepatocellular Carcinoma. The Advanced Hepatocellular Carcinoma companies which have their Advanced Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, CStone Pharmaceuticals.

 

DelveInsight’s Advanced Hepatocellular Carcinoma pipeline report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Advanced Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Advanced Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Learn more about the emerging Advanced Hepatocellular Carcinoma Pipeline Therapies @ Advanced Hepatocellular Carcinoma Clinical Trials Assessment

 

Scope of the Advanced Hepatocellular Carcinoma Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
• Advanced Hepatocellular Carcinoma Pipeline Therapies- Enzalutamide, ABT-869, Durvalumab, Tremelimumab, Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules, Donafenib Tosilate Tablets, Toripalimab Injection, IBI308 200mg, Lenvatinib, Pembrolizumab, Cabozantinib, AEG35156 antisense IV infusion, Sorafenib, Z-208, Octreotide, and others.

 

Dive deep into rich insights for new drugs for Advanced Hepatocellular Carcinoma treatment, Visit @ Advanced Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Advanced Hepatocellular Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug name: Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. Nofazinlimab: CStone Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase I/II)
14. Tivozanib : AVEO Oncology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Advanced Hepatocellular Carcinoma Key Companies
21. Advanced Hepatocellular Carcinoma Key Products
22. Advanced Hepatocellular Carcinoma – Unmet Needs
23. Advanced Hepatocellular Carcinoma – Market Drivers and Barriers
24. Advanced Hepatocellular Carcinoma – Future Perspectives and Conclusion
25. Advanced Hepatocellular Carcinoma Analyst Views
26. Advanced Hepatocellular Carcinoma Key Companies
27. Appendix

 

For further information on the Advanced Hepatocellular Carcinoma Pipeline Therapeutics, reach out to Advanced Hepatocellular Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market